Benzinga's Top Upgrades, Downgrades For January 5, 2018

Top Upgrades

• Analysts at Bank of America upgraded Cisco Systems, Inc. CSCO from Neutral to Buy. Cisco shares rose 1.38 percent to $39.53 in pre-market trading.
• Barclays upgraded Target Corporation TGT from Underweight to Equal-Weight. Target shares climbed 0.84 percent to $66.40 in pre-market trading.
• Analysts at Barclays upgraded Lowe's Companies, Inc. LOW from Equal-Weight to Overweight. Lowe's shares gained 1 percent to $93.66 in pre-market trading.
• RBC Capital upgraded Boston Scientific Corporation BSX from Outperform to Top Pick. Boston Scientific shares dropped 0.04 percent to close at $25.32 on Thursday.
• Analysts at Argus upgraded Eli Lilly and Co LLY from Hold to Buy. Eli Lilly shares closed at $85.52 on Thursday.
• Analysts at Goldman Sachs upgraded Xilinx, Inc. XLNX from Neutral to Buy. Xilinx shares rose 2.45 percent to $72.22 in pre-market trading.
• PiperJaffray upgraded U.S. Bancorp USB from Neutral to Overweight. US Bancorp shares rose 0.22 percent to $55.10 in pre-market trading.
• Instinet upgraded Comerica Incorporated CMA from Neutral to Buy. Comerica shares closed at $87.51 on Thursday.
• Analysts at Baird upgraded United Technologies Corporation UTX from Neutral to Outperform. United Technologies shares closed at $130.45 on Thursday.
• JP Morgan upgraded Fiat Chrysler Automobiles NV FCAU from Neutral to Overweight. Fiat Chrysler shares rose 2.23 percent to $21.11 in pre-market trading.

Top Downgrades

• Evercore ISI Group downgraded Sabre Corp SABR from Outperform to Underperform. Sabre shares closed at $20.89 on Thursday.
• JP Morgan downgraded Masco Corp MAS from Overweight to Neutral. Masco shares closed at $44.05 on Thursday.
• Analysts at Baird downgraded Johnson Controls International plc JCI from Outperform to Neutral. Johnson Controls shares closed at $39.85 on Thursday.
• Analysts at Oppenheimer downgraded Synergy Pharmaceuticals Inc SGYP from Outperform to Perform. Synergy Pharmaceuticals shares fell 3.28 percent to $2.36 in pre-market trading.
• Wells Fargo downgraded Teva Pharmaceutical Industries Ltd (ADR) TEVA from Market Perform to Underperform. Teva Pharmaceutical dropped 1.94 percent to $19.20 in pre-market trading.
• Citigroup downgraded Roku Inc ROKU from Neutral to Sell. Roku shares fell 5.89 percent to $48.22 in pre-market trading.
• Citigroup downgraded Trivago NV - ADR TRVG from Buy to Neutral. trivago shares closed at $7.56 on Thursday.
• Wedbush downgraded Wingstop Inc WING from Outperform to Neutral. Wingstop shares dropped 1.15 percent to $40.28 in pre-market trading.
• William Blair downgraded Illumina, Inc. ILMN from Outperform to Market Perform. Illumina shares closed at $232.99 on Thursday.
• Bank of America downgraded Celgene Corporation CELG from Buy to Neutral. Celgene shares fell 0.63 percent to $106.01 in pre-market trading.

Top Initiations

• Buckingham initiated coverage on Nike Inc NKE with a Buy rating. The price target for Nike is set to $72. Nike shares closed at $63.44 on Thursday.
• Leerink Swann initiated coverage on Regulus Therapeutics Inc RGLS with an Outperform rating. The price target for Regulus Therapeutics is set to $2. Regulus Therapeutics shares closed at $1.18 on Thursday.
• Credit Suisse initiated coverage on Williams Companies Inc WMB with an Outperform rating. The price target for Williams is set to $36. Williams shares closed at $32.55 on Thursday.
• Analysts at Credit Suisse initiated coverage on Phillips 66 Partners LP PSXP with a Neutral rating. The price target for Phillips 66 Partners is set to $52. Phillips 66 Partners shares closed at $53.84 on Thursday.
• Credit Suisse initiated coverage on Kinder Morgan Inc KMI with an Outperform rating. The price target for Kinder Morgan is set to $23. Kinder Morgan shares closed at $19.01 on Thursday.
• Analysts at Citigroup initiated coverage on CytomX Therapeutics Inc CTMX with a Buy rating. The price target for CytomX Therapeutics is set to $40. CytomX Therapeutics shares closed at $22.87 on Thursday.
• Analysts at BTIG Research initiated coverage on Myriad Genetics, Inc. MYGN with a Buy rating. The price target for Myriad Genetics is set to $41. Myriad Genetics shares closed at $34.38 on Thursday.
• BMO Capital initiated coverage on Core-Mark Holding Company, Inc. CORE with a Market Perform rating. The price target for Core-Mark is set to $33. Core-Mark shares closed at $31.41 on Thursday.